GlassScriptPhysician profile
Edward G Myer
NPI 1487845541
$5,157.94
in general payments reported to CMS, 2019-2025
32 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,300 · 2020: $199 · 2021: $498 · 2022: $791 · 2023: $556 · 2024: $1,099 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.73 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $749.87 | 2019-2024 | Myrbetriq, Xtandi |
| Procept Biorobotics Corporation | $662.02 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $648.30 | 2019-2024 | Bard Urinary Drainage Bag |
| Pfizer INC. | $507.16 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $491.89 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $332.30 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $282.42 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.91 | 2022-2025 | |
| Abbvie INC. | $203.14 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $138.91 | 2024-2025 | Orgovyx |
| Comsort, INC | $100.00 | 2019 | |
| Rochester Medical Corporation | $84.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $82.69 | 2019-2024 | Keytruda, Welireg |
| Urogen Pharma, INC. | $77.18 | 2022-2025 | |
| Tolmar, INC. | $72.00 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.47 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $49.15 | 2020 | |
| Boston Scientific Corporation | $43.30 | 2019-2024 | Tria Firm |
| Endo USA, INC. | $40.47 | 2024-2025 | Edex, Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $36.96 | 2019 | |
| Progenics Pharmaceuticals, INC. | $34.88 | 2022-2025 | |
| Antares Pharma, INC. | $31.03 | 2025 | Xyosted |
| Myriad Genetic Laboratories, INC. | $28.83 | 2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $26.05 | 2025 | |
| Photocure INC | $25.66 | 2024 | Cysview |
| Blue Earth Diagnostics | $23.87 | 2019 | |
| Immunitybio, INC. | $19.75 | 2024 | |
| Telix Pharmaceuticals | $19.20 | 2025 | |
| Laborie Medical Technologies Corp. | $18.16 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Astrazeneca Pharmaceuticals LP | $17.11 | 2020 | |
| Rayner Intraocular Lenses Limited | $14.66 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Palette Life Sciences, INC. | $13.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Myer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.